Chardan Capital Markets Downgrades Intellia Therapeutics (NTLA) to Neutral

August 29, 2017 3:20 AM EDT


Send to a Friend

Chardan Capital Markets downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $20.00.Analyst Madhu Kumar …

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to Premium below (Free Trial)

Leave a Reply

Your email address will not be published. Required fields are marked *


12 − 11 =